Kędra Kamila, Reich Adam
Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, 35-055, Poland.
Doctoral School, University of Rzeszow, Rzeszow, Poland.
Drug Des Devel Ther. 2024 Dec 8;18:5827-5839. doi: 10.2147/DDDT.S240867. eCollection 2024.
Plaque-type psoriasis is a chronic immune-mediated inflammatory skin disease of uncertain etiology, significantly impacting patient well-being. This chronic condition not only contributes to stigmatization and mental health challenges but also poses an independent risk for cardiovascular and other comorbid diseases. Affecting approximately 60 million people globally, psoriasis manifests primarily as mild-to-moderate disease in about 80% of cases, where topical therapy is pivotal. The most commonly used topical antipsoriatic therapy involves a combination of vitamin D3 analog (calcipotriene - Cal) and a synthetic potent corticosteroid (betamethasone dipropionate - BD). Various formulations of Cal/BD, including ointment, gel (topical suspension), and aerosol foam, have been approved by the US Food and Drug Administration (FDA). The cream based on the PAD (Polyaphron Dispersion) technology is another formulation of this combination drug, expanding the therapeutic options for patients with psoriasis. This article summarizes the most relevant published studies concerning the efficacy and safety of different calcipotriol and betamethasone formulations treating of plaque-type psoriasis in patients aged 12 or older.
斑块型银屑病是一种病因不明的慢性免疫介导性炎症性皮肤病，对患者的健康有重大影响。这种慢性病不仅会导致污名化和心理健康问题，还会带来心血管疾病和其他合并症的独立风险。银屑病全球约有6000万人受影响，约80%的病例主要表现为轻至中度疾病，此时局部治疗至关重要。最常用的局部抗银屑病疗法是维生素D3类似物（卡泊三醇 - Cal）和合成强效皮质类固醇（二丙酸倍他米松 - BD）的联合使用。Cal/BD的各种剂型，包括软膏、凝胶（局部混悬剂）和气雾剂泡沫，已获美国食品药品监督管理局（FDA）批准。基于PAD（Polyaphron分散体）技术的乳膏是这种复方药物的另一种剂型，为银屑病患者扩展了治疗选择。本文总结了已发表的关于不同卡泊三醇和倍他米松制剂治疗12岁及以上斑块型银屑病患者的疗效和安全性的最相关研究。
